Skip to main content
  • Global
  • US
  • en
  • de

Search

Home

Flyout

  • Science

    Science

    Learn more
    • Pipeline
      • Tafasitamab
      • Pelabresib
      • Tulmimetostat
      • Clinical Trials
    • Research
      • Technology
    • Medical Congresses
  • Medicines
  • Company

    Company

    MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines.

    Learn more
    • Leadership
    • Responsibility
    • History
    • Our Commitment to People Living With Cancer
  • Careers

    Careers

    Learn more
    • Job Openings
  • Investors

    Investors

    Learn more
    • Financial Information
    • Corporate Governance
    • Stock Information
    • Annual General Meeting 2022
    • Archive of past Annual General Meetings
    • All Events & Conferences
  • Media

    Media

    Learn more
    • All news
  • Global
  • US
  • en
  • de
  1. Home
  2. Node

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

23.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

23.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

19.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

19.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

19.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

19.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

18.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

18.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

16.01.2023
voting rights

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

16.01.2023
voting rights

Pagination

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • Next › Next page
  • Last » Last page
Subscribe to

Footer-first-column

  • About Us
  • Leadership
  • Careers

Footer-second-column

  • Pipeline
  • Medicines
  • Clinical Studies

Footer-third-column

  • Investors
  • Media

Footer-fifth-column

  • Imprint
  • Terms and Conditions
  • Privacy Policy
  • Contact Us
© 2023 MorphoSys AG
CORP-GL-00127

You are now leaving the MorphoSys.com website. This link will take you to a different website. You are solely responsible for your interactions with that website.

Do you wish to proceed ?

  • Yes
  • No

MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.

  • Continue
  • Cancel
  • I am a U.S. Healthcare Professional
  • I am a U.S. Patient or Caregiver